Avidity Biosciences Statistics

Total Valuation

RNA has a market cap or net worth of $3.80 billion. The enterprise value is $2.22 billion.

Market Cap	3.80B
Enterprise Value	2.22B

Important Dates

The last earnings date was Thursday, November 7, 2024, after market close.

Earnings Date	Nov 7, 2024
Ex-Dividend Date	n/a

Share Statistics

RNA has 119.31 million shares outstanding. The number of shares has increased by 44.08% in one year.

Current Share Class	119.31M
Shares Outstanding	119.31M
Shares Change (YoY)	+44.08%
Shares Change (QoQ)	+15.38%
Owned by Insiders (%)	0.48%
Owned by Institutions (%)	87.61%
Float	92.35M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	285.57
PB Ratio	2.52
P/TBV Ratio	2.53
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	218.98
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 17.76, with a Debt / Equity ratio of 0.01.

Current Ratio	17.76
Quick Ratio	17.60
Debt / Equity	0.01
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -27.76% and return on invested capital (ROIC) is -19.90%.

Return on Equity (ROE)	-27.76%
Return on Assets (ROA)	-18.33%
Return on Capital (ROIC)	-19.90%
Revenue Per Employee	$39,988
Profits Per Employee	-$1.11M
Employee Count	253
Asset Turnover	0.01
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +249.29% in the last 52 weeks. The beta is 0.89, so RNA's price volatility has been lower than the market average.

Beta (5Y)	0.89
52-Week Price Change	+249.29%
50-Day Moving Average	42.44
200-Day Moving Average	37.16
Relative Strength Index (RSI)	31.67
Average Volume (20 Days)	1,356,353

Short Selling Information

Short Interest	14.94M
Short Previous Month	14.52M
Short % of Shares Out	15.44%
Short % of Float	n/a
Short Ratio (days to cover)	13.34

Income Statement

In the last 12 months, RNA had revenue of $10.12 million and -$280.49 million in losses. Loss per share was -$2.85.

Revenue	10.12M
Gross Profit	-250.67M
Operating Income	-324.69M
Pretax Income	-228.68M
Net Income	-280.49M
EBITDA	-322.04M
EBIT	-324.69M
Loss Per Share	-$2.85

Full Income Statement

Balance Sheet

The company has $1.59 billion in cash and $7.60 million in debt, giving a net cash position of $1.58 billion or $13.25 per share.

Cash & Cash Equivalents	1.59B
Total Debt	7.60M
Net Cash	1.58B
Net Cash Per Share	$13.25
Equity (Book Value)	1.50B
Book Value Per Share	12.64
Working Capital	1.53B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$184.50 million and capital expenditures -$4.01 million, giving a free cash flow of -$188.51 million.

Operating Cash Flow	-184.50M
Capital Expenditures	-4.01M
Free Cash Flow	-188.51M
FCF Per Share	-$1.58

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-3,209.34%
Pretax Margin	-2,772.44%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

RNA does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-44.08%
Shareholder Yield	-44.08%
Earnings Yield	-7.39%
FCF Yield	-4.97%

Analyst Forecast

The average price target for RNA is $64.36, which is 102.26% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$64.36
Price Target Difference	102.26%
Analyst Consensus	Strong Buy
Analyst Count	11
Revenue Growth Forecast (5Y)	131.43%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

RNA has an Altman Z-Score of 10.13 and a Piotroski F-Score of 2.

Altman Z-Score	10.13
Piotroski F-Score	2